LY3009120

Catalog No.S7842

LY3009120 Chemical Structure

Molecular Weight(MW): 424.51

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

Size Price Stock Quantity  
USD 147 In stock
USD 477 In stock
USD 997 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 6 Publications

5 Customer Reviews

  • B, VE or VELV were transiently transfected in SKBR3 for 24 hours. Then, the cells were treated with 1 μmol/L lapatinib for 1 hour, followed by treatment with DMSO or the RAF inhibitors indicated for 1 hour (the dose for vemurafenib, PLX7904, LY3009120, TAK632, BGB3245, and BGB3290 is 1 μmol/L; the dose for dabrafenib and PLX8394 is 300 nmol/L). Untransfected (UT) SKBR3 cells were treated with DMSO or 1 μmol/L lapatinib (lanes 1 and 2)

    Cancer Discov, 2018, 8(9):1130-1141. LY3009120 purchased from Selleck.

    (a) INA-6, MM.1S, KMS11 or U266 cells were treated for 24 h either with 50 μm of the pan-Raf inhibitor MLN-2480, or 20 μm (INA-6 and MM.1S) or 25 μm (KMS11 or U266) of the pan-Raf inhibitor LY3009120 before western analyses of MEK1/2 and ERK1/2 activation with phosphorylation-specific antibodies.

    Leukemia, 2017, 31(4):922-933. LY3009120 purchased from Selleck.

  • Immunoblotting of whole-cell lysates of WM1366 exposed to LY3009120 (1 μmol/L) and in combination with sorafenib (1 μmol/L) and aspirin (2 mmol/L) for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). β-Actin was used as loading control. Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. LY3009120 purchased from Selleck.

    E, Attenuation of the invasion capability of control gastric cancer cells by treatment with LY3009120 (20 μmol/L), a pan-Raf inhibitor, without effect on over-Kir2.1 gastric cancer cells. Data are shown as mean ± SD (n = 5; ***, P < 0.0001, Student t test). F, Attenuation of the level of pMEK1/2 and pERK1/2 in control gastric cancer cells by LY3009120 (20 μmol/L) treatment, without effect on over-Kir2.1 gastric cancer cells.

    Cancer Res, 2018, 78(11):3041-3053. LY3009120 purchased from Selleck.

  • Treatment of two PDXs (M048R2.X2 and M063R.X2) that express the BRAFV600E/DK with 30 mg/kg dabrafenib or 15 mg/kg LY3009120 (n=8 tumors/group). Graphs represent tumor volume and dashed lines indicate start of treatment. Unpaired t test was performed at the last time point (*p < 0.05 and ***p < 0.005). Error bars indicate SD. Lower part depicts the immunoblotting for p-ERK and BRAF on M048R2.X2 and M063R.X2, treated with either dabrafenib or LY3009120 (each lane represents a tumor derived from an individual mouse).

    Cell Rep, 2016, 16(1):263-77.. LY3009120 purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Targets
C-Raf [1]
(Cell-free assay)		 BRAF(V600E) [1]
(Cell-free assay)		 BRAF WT [1]
(Cell-free assay)
4.3 nM 5.8 nM 15 nM
In vitro

LY3009120 inhibits the cell growth of A375 and HCT116 cells with the IC50 of 9.2 and 220 μM, respectively. LY3009120 inhibits the tyrosine kinase KDR with the IC50 of 3.9 μM.[1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human A375 cells MlW3VJJwdGmoZYLheIlwdiCjc4PhfS=> NUn5OIpOPzJiaB?= M2XIS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nlicnXzZZp2emmwIHHzd4F6NCCLQ{WwQVkvOiCwTR?= NYPGeoFyOjV7NkW4NFQ>
human A375 cells MUPGeY5kfGmxbjDhd5NigQ>? MkPDNVUhdWmwcx?= NULWTY9HS2:vcHX0bZRqfmViYnnu[Ilv\yCjZn\pcol1gSC2bzDFdIhCOiCrbjDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDF3IH3pcpMhcW5icILld4Vv[2Vib3[gRXRRKGGwYXzv[5VmNCCLQ{WwQVAvODJizszN NVq5O2R3OjV7NkW4NFQ>
human A375 cells MXPGeY5kfGmxbjDhd5NigQ>? NInTO|cyPSCvaX7z MXvDc41x\XSrdHn2[UBjcW6maX7nJIFn\mmwaYT5JJRwKEKUQV[gbY4hcHWvYX6gRVM4PSClZXzsd{Bi\nSncjCxOUBucW6|IHnuJJBz\XOnbnPlJI9nKEGWUDDhcoFtd2e3ZTygTWM2OD1yLkCzNUDPxE1? M4fWbVI2QTZ3OEC0
human A375 cells MVPGeY5kfGmxbjDhd5NigQ>? NGTxPYk4OiCq NEXPTIVKdmirYnn0bY9vKG:oIFLSRWYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFGzO|Uh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDFVmsheGixc4Doc5J6dGG2aX;uJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDFUGlUSSCjc4PhfUwhUUN3ME2wMlA{PyEQvF2= MVSyOVk3PThyNB?=
human A375 cells NF3wS|NHfW6ldHnvckBie3OjeR?= NYnFe|dwOTVibXnudy=> M3f5OGNwdXCndHn0bZZmKGKrbnTpcoch[W[oaX7peJkhfG9iWlHLJIlvKGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNVUhdWmwczDpckBxemW|ZX7j[UBw\iCDVGCgZY5idG:pdXWsJGlEPTB;MD6wN|kh|ryP NE\iUFUzPTl4NUiwOC=>
human A375 cells NHPJcXVHfW6ldHnvckBie3OjeR?= NGfaRWwyPSCvaX7z MWrDc41x\XSrdHn2[UBjcW6maX7nJIFn\mmwaYT5JJRwKHB|ODDpckBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEG1JI1qdnNiaX6gdJJme2WwY3Wgc4YhSVSSIHHuZYxw\3WnLDDJR|UxRTBwME[xJO69VQ>? M4S4[|I2QTZ3OEC0
human HCT116 cells NWXzcIhHTnWwY4Tpc44h[XO|YYm= M3\O[GlvcGmkaYTpc44hd2ZiS2LBV{BIOTOGIH31eIFvfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDFVmsheGixc4Doc5J6dGG2aX;uJIJ6KEWOSWPBMEBKSzVyPUCuNVUh|ryP Mli2NlU6PjV6MES=
human HCT116 cells NYTRcGpzWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXu2O{Bp NX\1fYVKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOlchcHK|IHL5JJJme2G8dYLpckBie3OjeTygTWM2OD1yLkKyJO69VQ>? M1HRb|I2QTZ3OEC0

... Click to View More Cell Line Experimental Data
In vivo In rats bearing BRAF V600E ST019VR PDX tumors, LY3009120 (15 or 30 mg/kg, p.o.) shows a dose-dependent tumor growth inhibition. In nude rats bearing A375 xenograft, single dose oral treatment with LY3009120 (3 to 50 mg/kg, p.o.) shows a dose dependent inhibition of phospho-ERK, with a dose for 50% inhibition of phospho-ERK (EC50) of 4.36 mg/kg, with plasma concentration to achieve 50% inhibition of phospho-ERK (EC50) of 68.9 ng/mL or 165 nM.[1]

Protocol

Kinase Assay:[2]
+ Expand

Kinase activity measurement using KiNativ assays:

Compounds are screened in A375 cell lysates using the ATP-based probe at 5 µM. IC50 values are reported in micromolar units. Cell pellets are resuspended in four volumes of lysis buffer [25 mM Tris pH 7.6, 150 mM NaCl, 1% CHAPS, 1% Tergitol NP-40 type, 1% v/v phosphatase inhibitor cocktail II], sonicated using a tip sonicator, and dounce homogenized. Lysates are cleared by centrifugation at 100,000 g for 30 min. The cleared lysates are filtered through a 0.22 μM syringe filter, and gel filtered into reaction buffer [20 mM Hepes pH 7.8, 150 mM NaCl, 0.1% triton X-100, 1% v/v phosphatase inhibitor cocktail II]. MnCl2 is then added to the lysate to a final concentration of 20 mM prior to inhibitor treatment and probe labeling. Final inhibitor concentrations used for IC50 determinations are 10, 1, 0.1, and 0.01 μM. ATP competition experiments are performed at 1,000, 100, 10, and 1 μM ATP. All inhibitor treatments are performed at room temperature.
Cell Research:[1]
+ Expand
  • Cell lines: A375 and HCT116 cells
  • Concentrations: 0.51 μM
  • Incubation Time: 67 h
  • Method: Briefly, cells are grown in DMEM high glucose supplemented with 10% characterized fetal bovine serum and 1% penicillin/streptomycin/L -glutamine at 37℃, 5% CO2, and 95% humidity. Cells are allowed to expand until 70-95% confluency. A serial dilution of test compound is dispensed into a 384-well black clear bottom plate. 625 cells are added per well in 50 μL of complete growth medium. Plates are incubated for 67 h at 37℃, 5% CO2 , and 95% humidity. Then, 10 μL of a 440 μM solution of resazurin in PBS is added to each well of the plate and plates are incubated for an additional 5 h at 37℃, 5% CO2, and 95% humidity. Plates are read on a Synergy2 reader using an excitation of 540 nm and an emission of 600 nm. Data are analyzed using Prism software to calculate IC 50 values.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female NIH nude rats bearing BRAF V600E ST019VR PDX tumors
  • Formulation: 20% cyclodextrin, 25 mM phosphate, pH2.0
  • Dosages: 30 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL warmed (7.06 mM)
Water Insoluble
Ethanol Insoluble warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC Na
For best results, use promptly after mixing. 		30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 424.51
Formula

C23H29FN6O
CAS No. 1454682-72-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02014116 Active not recruiting Neoplasms|Neoplasm Metastasis|Melanoma|Carcinoma Non-Small-Cell Lung|Colorectal Neoplasms Eli Lilly and Company November 26 2013 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am trying to figure out solubility of the drug LY3009120 Catalog #7842 for in vivo studies. I need some details on the formulation and how it is made to dissolve the chemical?

  • Answer:

    It can dissolve in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 1 mg/ml clearly, and in 0.5% CMC Na at 30 mg/ml as a suspension.

selleck catalog

Raf Signaling Pathway Map

Related Raf Products0

  • Ravoxertinib (GDC-0994) New

    GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

  • Ulixertinib (BVD-523, VRT752271) New

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • Cobimetinib (GDC-0973, RG7420) New

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-RafV600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

    Features:A novel and potent inhibitor of the B-RAFV600E oncoprotein.

  • Dabrafenib (GSK2118436)

    Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

  • Sorafenib

    Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • Sorafenib Tosylate

    Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • PLX-4720

    PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

  • TAK-632

    TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.

  • GDC-0879

    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.

Tags: buy LY3009120 | LY3009120 supplier | purchase LY3009120 | LY3009120 cost | LY3009120 manufacturer | order LY3009120 | LY3009120 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID